Ratings by Ladenburg Thalmann (Jeff Cohen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/15/2026 | Legacy Reserves | LGCY | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2026 | Alpha Tau Medical Ltd. | DRTS | Maintain | Buy (N/A) |
|
Details | ||
| 4/10/2026 | Artivion Inc. | AORT | Upgrade | Buy (Neutral) |
36.51 (25.42) |
-30.38% | Details | |
| 2/13/2026 | Artivion Inc. | AORT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/13/2026 | Legacy Reserves | LGCY | Maintain | Buy (N/A) |
|
Details | ||
| 11/14/2025 | Legacy Reserves | LGCY | Maintain | Buy (N/A) |
|
Details | ||
| 11/7/2025 | Artivion Inc. | AORT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/13/2025 | Artivion Inc. | AORT | Downgrade | Neutral (Buy) |
43.85 (36.51) |
-16.74% | Details | |
| 10/22/2024 | Legacy Reserves | LGCY | New Coverage | Buy (N/A) |
5.89 (10.87) |
84.55% | Details | |
| 9/5/2023 | Sonoma Pharmaceuticals | SNOA | New Coverage | Buy (N/A) |
0.92 (1.30) |
41.3% | Details | |
| 9/5/2023 | SCYNEXIS | SCYX | New Coverage | Buy (N/A) |
3.65 (5.25) |
43.84% | Details | |
| 8/4/2022 | Fortress Biotech | FBIO | New Coverage | Buy (N/A) |
1.00 (2.71) |
171% | Details |
